One hundred and eighty-six patients fulfilling the inclusion criteria will be randomized to one of the two assessments of endovascular repair to treat de novo femoropopliteal lesions 14 cm in symptomatic patients ( Rutherford 2 to 5 ) : bare stent group and paclitaxel eluting stent group .